Neoadjuvant camrelizumab combined with chemotherapy for resectable stage IIIA-IIIb non-small cell lung cancer: Single arm phase II study.
G Cai, K Wang, X Wang, J Zhao, X Han, H Zhou, C Xie… - 2024 - ascopubs.org
e20074 Background: This study aimed to evaluate the safety and efficacy of neoadjuvant
camrelizumab combined with chemotherapy in patients with resectable non-small cell lung …
camrelizumab combined with chemotherapy in patients with resectable non-small cell lung …
Neoadjuvant camrelizumab plus platinum-based chemotherapy vs chemotherapy alone for chinese patients with resectable stage IIIA or IIIB (T3N2) non–small cell …
J Lei, J Zhao, L Gong, Y Ni, Y Zhou, F Tian, H Liu… - JAMA …, 2023 - jamanetwork.com
Importance The benefit of neoadjuvant camrelizumab plus chemotherapy for resectable
stage IIIA or IIIB non–small cell lung cancer (NSCLC) remains unknown. Objective To …
stage IIIA or IIIB non–small cell lung cancer (NSCLC) remains unknown. Objective To …
Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases
X Li, C Xia, M Liu, J Liu, M Dong, H Zhao, S Xu… - Frontiers in …, 2022 - frontiersin.org
Neoadjuvant immunochemotherapy has attracted much attention as a treatment for locally
advanced non-small-cell lung cancer. However, there is scarce evidence of the safety and …
advanced non-small-cell lung cancer. However, there is scarce evidence of the safety and …
Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II–III non-small-cell lung …
H Xia, H Zhang, Z Ruan, H Zhang, L Sun… - … and Targeted Therapy, 2024 - nature.com
This multicentre, two-arm, phase 2 study aimed to explore the efficacy and safety of
neoadjuvant camrelizumab plus chemotherapy or apatinib in patients with initially …
neoadjuvant camrelizumab plus chemotherapy or apatinib in patients with initially …
1296P Neoadjuvant camrelizumab and apatinib in patients with resectable non-small-cell lung cancer: One-year update from a phase II trial
W Guo, L Zhao, J Zhao, S Wang, X Tao, L Li… - Annals of …, 2023 - annalsofoncology.org
Background Our phase 2 trial was the first to report the efficacy and safety of neoadjuvant
chemo-free regimen with camrelizumab and apatinib in patients with resectable non-small …
chemo-free regimen with camrelizumab and apatinib in patients with resectable non-small …
56O A randomized, controlled, multicenter phase II trial of camrelizumab combined with albumin-bound paclitaxel and cisplatin as neoadjuvant treatment in resectable …
J Lei, J Zhao, X Yan, L Gong, G Lei… - Immuno-Oncology and …, 2022 - esmoiotech.org
Background Resectable NSCLC with neoadjuvant chemotherapy (CT) has favourable
outcomes. However, with few neoadjuvant immunotherapy trials, detailed information on …
outcomes. However, with few neoadjuvant immunotherapy trials, detailed information on …
Neoadjuvant camrelizumab for non-small cell lung cancer: a retrospective multicenter, real-world study (CTONG2004)
SY Liu, Q Chen, C Zhou, H Zhang, W Li, J Chen… - Cancer Immunology …, 2023 - Springer
Background Camrelizumab has shown encouraging efficacy in advanced non-small cell
lung cancer (NSCLC), either as monotherapy or combined with chemotherapy. However …
lung cancer (NSCLC), either as monotherapy or combined with chemotherapy. However …
Efficacy and safety of camrelizumab (a PD‑1 inhibitor) combined with chemotherapy as a neoadjuvant regimen in patients with locally advanced non‑small cell lung …
X Hou, X Shi, J Luo - Oncology Letters, 2022 - spandidos-publications.com
Camrelizumab is a novel programmed cell death protein 1 (PD‑1) inhibitor developed in
China that exhibits good efficacy in several advanced cancer types, including non‑small cell …
China that exhibits good efficacy in several advanced cancer types, including non‑small cell …
[HTML][HTML] Neoadjuvant pembrolizumab and chemotherapy in resectable clinical stage III non-small-cell lung cancer: a retrospective cohort study
G Zhao, H Zhang, F Xu, C Lu, Q Zhu… - Translational Lung …, 2023 - ncbi.nlm.nih.gov
Background Pembrolizumab has been shown to be effective and safe in improving the
survival of patients with advanced non-small-cell lung cancer (NSCLC). However, the …
survival of patients with advanced non-small-cell lung cancer (NSCLC). However, the …
98P Camrelizumab as neoadjuvant, first-or later-line treatment for non-small cell lung cancer (NSCLC): a retrospective real-world study (CTONG2004)
C Xu, Q Chen, C Zhou, L Wu, W Li… - Annals of …, 2021 - annalsofoncology.org
Background Camrelizumab (anti-PD-1 antibody) monotherapy or combined with
chemotherapy showed efficacy for advanced NSCLC in trials. However, the real-world data …
chemotherapy showed efficacy for advanced NSCLC in trials. However, the real-world data …
相关搜索
- resectable stage neoadjuvant camrelizumab
- lung cancer neoadjuvant camrelizumab
- iiia iiib neoadjuvant camrelizumab
- arm phase neoadjuvant camrelizumab
- cell lung cancer
- resectable stage lung cancer
- arm phase iiia iiib
- resectable stage arm phase
- resectable stage iiia iiib
- chemotherapy in patients neoadjuvant camrelizumab
- chemotherapy in patients lung cancer
- resectable stage chemotherapy in patients
- clinical experience neoadjuvant camrelizumab
- retrospective multicenter neoadjuvant camrelizumab
- chemotherapy alone stage iiia
- lung cancer clinical experience